Abstract 3514: Histone deacetylase 9 (HDAC9) mediates therapy resistance by regulating tumor-neutrophil interaction in advanced hepatocellular carcinoma

Abstract Tyrosine kinase inhibitors (TKIs) and immune checkpoint blockade (ICB) therapies are standard treatments for advanced hepatocellular carcinoma (HCC), but their efficacy is limited by therapy resistance. This study investigates the mechanisms underlying resistance, focusing on the role of tumor-immune interaction. Using single-cell RNA sequencing (scRNA-seq) in a TKI-treated immunocompetent mouse model, we identified an expansion of poorly differentiated tumor cells with significant upregulation of histone deacetylase 9 (HDAC9). Elevated HDAC9 enhanced cancer stemness and reduced the efficacy of TKI therapy. Beyond TKIs, HDAC9 also contributed to ICB resistance by suppressing CD8+ T cell infiltration and cytotoxicity, partly through interactions with immunosuppressive neutrophils exhibiting a neutrophil extracellular trap (NET) phenotype. Neutrophil depletion reversed ICB resistance, restoring CD8+ T cell infiltration and function. Mechanistically, HDAC9 deacetylates translation initiation factor 4 gamma 2 (eIF4G2), enhancing its interaction with YTHDF3 to promote m6A-dependent protein translation, including signaling molecules that mediate tumor-neutrophil crosstalk. Clinicopathological analysis confirmed that HDAC9 correlates with increased neutrophil infiltration and reduced cytotoxic immune activity in HCC patients. These findings identify HDAC9 as a key immunoregulator driving therapy resistance and suggest that targeting the HDAC9/eIF4G2/YTHDF3 axis may improve the efficacy of TKI and ICB therapies in advanced HCC. Citation Format: Yunong Xie, Minghe Zhang, Linglin Liu, Yimiao He, Jiahuan Cai, Clive Yik-Sham Chung, Leung Hoi Wing, Terence Kin-Wah Lee, Stephanie Ma, Ka-Fai To, Jingying Zhou, Carol Man Carol Tong. Histone deacetylase 9 (HDAC9) mediates therapy resistance by regulating tumor-neutrophil interaction in advanced hepatocellular carcinoma abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3514.